In the past two years, clinical trials in India have come increasingly under public scrutiny. As a result, clinical research organisations (CROs), companies that conduct clinical trials for drug makers, are somewhat under pressure.

However, leading CROs in the country, such as Quintiles, are riding on the hope that they will be able to redeem the opportunities in the sector once the regulatory system is set right. As that happens, the threat to this area, where India till recently had a lead over China, shall be overcome, and things will be back to normal.